Skip to search formSkip to main contentSkip to account menu

CYT997

Known as: Tubulin Inhibitor CYT997 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The incidence rate of head and neck squamous cell carcinoma (HNSCC) has steadily increased over the past decade. However… 
2018
2018
The functional relationship between apoptosis and autophagy in anticancer drug treatment is extremely complex, and the molecular… 
2017
2017
BackgroundAbnormalities of tubulin polymerization and microtubule assembly are often seen in cancer, which make them very… 
2013
2013
The orally active microtubule-depolymerizing agent CYT997 is potently cytotoxic to a variety of tumors in vitro and in vivo… 
2012
2012
SummaryPurpose CYT997 is a novel microtubule inhibitor and vascular disrupting agent. This phase I trial examined the safety… 
2011
2011
The orally active microtubule-disrupting agent (S)-1-ethyl-3-(2-methoxy-4-(5-methyl-4-((1-(pyridin-3-yl)butyl)amino)pyrimidin-2… 
2011
2011
SummaryMultiple Myeloma (MM) is an incurable malignancy of mature plasma cells. Microtubule targeting agents (MTAs) are an… 
2010
2010
Background:CYT997 is a novel microtubule inhibitor and vascular-disrupting agent with marked preclinical anti-tumour activity… 
2009
2009
CYT997 is a wholly synthetic compound that possesses highly potent cytotoxic activity in vitro through inhibition of microtubule…